BioCentury
ARTICLE | Company News

Presage, Celgene in cancer deal

March 6, 2013 2:28 AM UTC

Presage Biosciences (Seattle, Wash.) partnered with Celgene Corp. (NASDAQ:CELG) to use Presage's technology to identify new drug combinations for solid tumors indications. Presage will receive $5 million up front in research funding and an $8 million equity investment. The biotech is also eligible for "substantial," undisclosed milestone payments. Presage's in vivo screening platform enables simultaneous comparison of up to four treatments within a single tumor in a live mouse via microdose bands. ...